Item 1.01. Entry into a Material Definitive Agreement

On November 16, 2020, Roth CH Acquisition I Co., a Delaware corporation ("ROCH"), Roth CH Acquisition I Co. Parent Corp., a Delaware corporation ("ParentCo"), Roth CH Merger Sub LLC, a Delaware limited liability company ("Merger Sub LLC"), Roth CH Merger Sub Corp., a Delaware corporation ("Merger Sub Corp") and PureCycle Technologies LLC, a Delaware limited liability company ("PCT"), entered into an agreement and plan of merger (the "Merger Agreement") pursuant to which ROCH will acquire PCT for consideration of a combination of shares in ParentCo and assumption of indebtedness (as further explained below). The terms of the Merger Agreement, which contains customary representations and warranties, covenants, closing conditions and other terms relating to the mergers and the other transactions contemplated thereby, are summarized below. Capitalized terms used in this Current Report on Form 8-K but not otherwise defined herein have the meanings given to them in the Merger Agreement.





The Merger Agreement


Structure of the Transaction

The acquisition is structured as a "double dummy" transaction, resulting in the following:





  (a)  Each of ParentCo, Merger Sub Corp and Merger Sub LLC are newly formed
       entities that were formed for the sole purpose of entering into and
       consummating the transactions set forth in the Merger Agreement. ParentCo
       is a wholly-owned direct subsidiary of ROCH and both Merger Sub LLC and
       Merger Sub Corp are wholly-owned direct subsidiaries of ParentCo.

  (b)  Upon Closing: (i) Merger Sub Corp will merge with and into ROCH (the "RH
       Merger"), with ROCH surviving the RH Merger as a wholly owned subsidiary of
       ParentCo (the "ROCH Surviving Company"); (ii) simultaneously with the RH
       Merger, Merger Sub LLC will merge with and into PCT (the "PCT Merger"),
       with PCT surviving the PCT Merger as a wholly-owned subsidiary of ParentCo
       (the "PCT Surviving Company"); and (iii) following the PCT Merger, ParentCo
       will contribute to the PCT Surviving Company the proceeds of the PIPE
       Placement (as defined below), other than the par value of the ROCH Common
       Stock, which will have been disbursed to ROCH, within two days following
       the Closing. ROCH Surviving Company will acquire, and ParentCo will
       contribute to ROCH Surviving Company (the "ParentCo Contribution") all
       units of the PCT Surviving Company directly held by ParentCo after the PCT
       Merger, such that, following the ParentCo Contribution, the PCT Surviving
       Company will be a wholly-owned subsidiary of the ROCH Surviving Company
       (together with the RH Merger, the PCT Merger and the other transactions
       related thereto, the "Proposed Transactions").

  (c)  Prior to or contemporaneously with the execution of the Merger Agreement,
       several investors entered into certain subscription or unit purchase
       agreements (collectively, the "Subscription Agreements"), pursuant to which
       such investors purchased (in the case of membership units of PCT) and
       agreed to purchase (in the case of ROCH Common Stock) (i) membership units
       of PCT at an effective price per ParentCo Common Share (as defined below)
       of approximately $8.35 per share for an aggregate cash amount of
       approximately $60 million, and (ii) at Closing, ROCH Common Stock at a
       purchase price of $10.00 per share, for an aggregate cash amount of $250
       million, in each case to be exchanged for shares of ParentCo common stock,
       par value $0.001 per share ("ParentCo Common Shares") in the Proposed
       Transactions.

  (d)  In addition, contemporaneously with the execution of the Merger Agreement,
       (i) certain holders of PCT's membership units ("PCT Securityholders")
       representing at least 70% of PCT's outstanding membership interests entered
       into a Company Support Agreement (the "Company Support Agreement"),
       pursuant to which such PCT Securityholders agreed, among other things, to
       approve the Merger Agreement and the Proposed Transactions, and (ii)
       certain holders of ROCH's common stock, par value $0.0001 per share ("ROCH
       Common Stock"), entered into a Founder Support Agreement (the "Founder
       Support Agreement"), pursuant to which, among other things, such holders of
       ROCH Common Stock agreed to approve the Merger Agreement and the Proposed
       Transactions.



At the Closing of the transactions contemplated by the Merger Agreement, certain PCT Securityholders representing at least 70% of PCT's outstanding membership interests and certain holders of ROCH Common Stock will also enter into an Investor Rights Agreement (the "Investor Rights Agreement"), which is a closing condition of the parties to consummate the Proposed Transactions. Pursuant to the Investor Rights Agreement, such PCT Securityholders have agreed to vote in favor of two board designees nominated by a majority of such holders of ROCH Common Stock for a period of two years following the Closing Date (the "IRA Designees"), provided that in the event a majority of the holders of the Pre-PIPE Shares (as defined below) choose to select one of the IRA Designees, the majority of such holders of ROCH Common Stock will select one of the IRA Designees and such holders of the Pre-PIPE Shares will select the other. The holders of the Pre-PIPE Shares may continue to select an IRA Designee until they no longer hold 10% or more of the outstanding ParentCo Common Shares. Such PCT Securityholders have also agreed, subject to certain exceptions, not to transfer ParentCo Common Shares received as PCT Merger Consideration (as defined below) except as follows:

· From and after the six-month anniversary of the Closing Date, each Founder (as


   defined in the Merger Agreement) may sell up to 20% of such Founder's ParentCo
   Common Shares and each PCT Securityholder that is not a Founder may sell up to
   33.34% of such PCT Securityholder's ParentCo Common Shares.

· From and after the one-year anniversary of the Closing Date, each Founder may


   sell up to an additional 30% of such Founder's ParentCo Common Shares and each
   PCT Securityholder that is not a Founder may sell up to an additional 33.33% of
   such PCT Securityholder's ParentCo Common Shares.









· From and after the Ironton, Ohio plant becoming operational, as certified by an


   independent engineering firm, each Founder may sell up to an additional 50% of
   such Founder's ParentCo Common Shares and each PCT Securityholder that is not a
   Founder may sell up to an additional 33.33% of such PCT Securityholder's shares
   of ParentCo Common Shares.




Consideration



The aggregate consideration payable to the PCT Securityholders for the Proposed Transactions (the "PCT Merger Consideration") consists of ParentCo Common Shares issued on the Closing Date (the "Share Consideration"), up to 4,000,000 additional ParentCo Common Shares upon the achievement of certain targets (the "Earnout Shares") and the assumption of all indebtedness related to (a) the Limited Offering Memorandum, dated September 23, 2020 (in connection with the . . .

Item 3.02. Unregistered Sales of Equity Securities.

The disclosure set forth above in Item 1.01 of this Current Report on Form 8-K under the heading "Subscription Agreements and PIPE Registration Rights Agreements" is incorporated by reference herein. The PIPE Shares that may be issued in connection with the applicable Subscription Agreements will not be registered under the Securities Act in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder.

Item 7.01. Regulation FD Disclosure.

On November 16, 2020, ROCH and PCT issued a joint press release announcing the execution of the Merger Agreement. A copy of the press release, which includes a link to a presentation containing additional information regarding the Proposed Transactions, is attached hereto as Exhibit 99.1 and incorporated herein by reference. Such exhibit and the information set forth therein shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise be subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act, or the Exchange Act.

Attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference is the form of presentation to be used by ROCH in presentations for certain of ROCH's securityholders and other persons. Such exhibits and the information set forth therein shall not be deemed to be filed for purposes of Section 18 of the Exchange Act, or otherwise be subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act.





Additional Information


In connection with the Proposed Transactions, ParentCo intends to file with the SEC a registration statement on Form S-4 that will include a proxy statement for the stockholders of ROCH that also constitutes a prospectus of ParentCo. ROCH urges investors, stockholders and other interested persons to read, when available, the preliminary proxy statement/prospectus as well as other documents filed with the SEC because these documents will contain important information about ROCH, ParentCo, PCT and the Proposed Transactions. After the registration statement is declared effective, the definitive proxy statement/prospectus to be included in the registration statement will be mailed to stockholders of ROCH as of a record date to be established for voting on the Proposed Transactions. Stockholders will also be able to obtain a copy of the proxy statement/prospectus, without charge by directing a request to: Roth CH Acquisition I Co., 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660. The preliminary and definitive proxy statement/prospectus to be included in the registration statement, once available, can also be obtained, without charge, at the SEC's website (www.sec.gov).

Participants in the Solicitation

ROCH, ParentCo, PCT and their respective directors and executive officers may be considered participants in the solicitation of proxies with respect to the Proposed Transactions under the rules of the SEC. Information about the directors and executive officers of ROCH is set forth in ROCH's Prospectus relating to its initial public offering (the "IPO Prospectus"), which was filed with the SEC on May 6, 2020. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the stockholders in connection with the Proposed Transactions will be set forth in the proxy statement/prospectus when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated above.





Non-Solicitation


This Current Report on Form 8-K is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Proposed Transactions and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of ROCH, ParentCo or PCT, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a definitive prospectus meeting the requirements of the Securities Act.





Forward-Looking Statements


This Current Report on Form 8-K and the attachments hereto contain forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, including statements about the parties' ability to close the Proposed Transactions, the anticipated benefits of the Proposed Transactions, and the financial condition, results of operations, earnings outlook and prospects of ROCH and/or PCT and may include statements for the period following the consummation of the Proposed Transactions. In addition, any statements that refer to projections (including EBITDA, EBITDA margin and revenue projections), forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as "plan," "believe," "expect," "anticipate," "intend," "outlook," "estimate," "forecast," "project," "continue," "could," "may," "might," "possible," "potential," "predict," "should," "would" and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements are based on the current expectations of the management of ROCH and PCT as applicable and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to those discussed and identified in public filings made with the SEC by ROCH and the following:





       ·   PCT's ability to meet, and to continue to meet, applicable regulatory
           requirements for the use of PCT's UPRP in food grade applications;
       ·   PCT's ability to comply on an ongoing basis with the numerous
           regulatory requirements applicable to the UPRP and PCT's facilities;
       ·   expectations regarding PCT's strategies and future financial
           performance, including its future business plans or objectives,
           prospective performance and opportunities and competitors, revenues,
           products and services, pricing, operating expenses, market trends,
           liquidity, cash flows and uses of cash, capital expenditures, and PCT's
           ability to invest in growth initiatives and pursue acquisition
           opportunities;
       ·   PCT's ability to scale and build Plant 1 in a timely and cost-effective
           manner;
       ·   the implementation, market acceptance and success of PCT's business
           model and growth strategy;
       ·   the success or profitability of PCT's offtake arrangements;
       ·   PCT's future capital requirements and sources and uses of cash;
       ·   PCT's ability to obtain funding for its operations and future growth;
       ·   developments and projections relating to PCT's competitors and
           industry;
       ·   the occurrence of any event, change or other circumstances that could
           give rise to the termination of the Merger Agreement;
       ·   the outcome of any legal proceedings that may be instituted against
           ROCH or PCT following announcement of the Merger Agreement and the
           transactions contemplated therein;
       ·   the inability to complete the Proposed Transactions due to, among other
           things, the failure to obtain ROCH stockholder approval or ROCH's
           inability to obtain the financing necessary to consummate the Proposed
           Transactions;
       ·   the risk that the announcement and consummation of the Proposed
           Transactions disrupts PCT's current plans;
       ·   the ability to recognize the anticipated benefits of the Proposed
           Transactions;
       ·   unexpected costs related to the Proposed Transactions;












       ·   the amount of any redemptions by existing holders of ROCH Common Stock
           being greater than expected;
       ·   limited liquidity and trading of ROCH's securities;
       ·   geopolitical risk and changes in applicable laws or regulations;
       ·   the possibility that ROCH and/or PCT may be adversely affected by other
           economic, business, and/or competitive factors;
       ·   operational risk;
       ·   risk that the COVID-19 pandemic, and local, state, and federal
           responses to addressing the pandemic may have an adverse effect on our
           business operations, as well as our financial condition and results of
           operations; and
       ·   the risks that the consummation of the Proposed Transactions is
           substantially delayed or does not occur.



Should one or more of these risks or uncertainties materialize or should any of the assumptions made by the management of ROCH and PCT prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.

All subsequent written and oral forward-looking statements concerning the Proposed Transactions or other matters addressed in this Current Report on Form 8-K and attributable to ROCH, PCT or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Current Report on Form 8-K. Except to the extent required by applicable law or regulation, ROCH and PCT undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of Current Report on Form 8-K to reflect the occurrence of unanticipated events.

Non-GAAP Financial Measure and Related Information

This Current Report on Form 8-K references EBITDA and EBITDA margin, which are financial measures that are not prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These non-GAAP financial measures do not have a standardized meaning, and the definition of EBITDA used by PCT may be different from other, similarly named non-GAAP measures used by others. In addition, such financial information is unaudited and does not conform to SEC Regulation S-X and as a result such information may be presented differently in future filings by PCT with the SEC.

Item 9.01. Financial Statements and Exhibits.





Exhibit No.   Description

  2.1           Agreement and Plan of Merger, dated as of November 16, 2020, by and
              among Roth CH Acquisition I Co., Roth CH Acquisition I Co. Parent
              Corp., Roth CH Merger Sub Corp., Roth CH Merger Sub, LLC and PureCycle
              Technologies, LLC
  10.1          Founder Support Agreement, dated as of November 16, 2020, by and
              among Roth CH Acquisition I Co., PureCycle Technologies, LLC and
              founding stockholders of Roth CH Acquisition I Co.
  10.2          Company Support Agreement, dated as of November 16, 2020, by and
              among PureCycle Technologies, LLC, Roth CH Acquisition I Co. and
              founding members of PureCycle Technologies, LLC
  10.3          Form of Subscription Agreement for the PIPE Placement
  10.4          Form of PIPE Registration Rights Agreement
  99.1          Press Release, dated November 16, 2020
  99.2          Investor Presentation dated November 2020

© Edgar Online, source Glimpses